Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription drugs, a mindset ill-suited for a growing wave of expensive medicines that treat rare diseases, according to a new report by a think tank.
The report by the libertarian-leaning Pioneer Institute challenged how the nonprofit Institute for Clinical and Economic Review, or ICER, gauges what drugs should cost.
The watchdog’s real agenda, said the Pioneer report, is simply to build pressure on drug firms to cut prices.
